Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1989 1
1991 2
1992 1
1993 3
1994 3
1995 3
1996 1
1997 1
1998 6
1999 3
2000 1
2001 2
2002 5
2003 1
2004 7
2005 4
2006 2
2007 3
2008 4
2009 3
2010 7
2011 6
2012 13
2013 29
2014 23
2015 32
2016 49
2017 42
2018 37
2019 48
2020 47
2021 34
2022 20
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 26327518

399 results

Results by year

Filters applied: . Clear all
Page 1
Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL, Horn S, Murali R, Möller I, Sucker A, Sondermann W, Stiller M, Schilling B, Livingstone E, Zimmer L, Reis H, Metz CH, Zeschnigk M, Paschen A, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG. Scholz SL, et al. Oncotarget. 2015 Sep 22;6(28):25868-82. doi: 10.18632/oncotarget.4665. Oncotarget. 2015. PMID: 26327518 Free PMC article.
Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE, Ober K, Dubbink HJ, Paridaens D, Naus NC, Belunek S, Krist B, Post E, Zwarthoff EC, de Klein A, Verdijk RM; Rotterdam Ocular Melanoma Study Group. Koopmans AE, et al. Invest Ophthalmol Vis Sci. 2014 Aug 26;55(9):6024-30. doi: 10.1167/iovs.14-14901. Invest Ophthalmol Vis Sci. 2014. PMID: 25159205
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, Carrera C, Schimming T, Möller I, Schwamborn M, Sucker A, Hillen U, Badenas C, Malvehy J, Zimmer L, Scherag A, Puig S, Schadendorf D. Griewank KG, et al. J Natl Cancer Inst. 2014 Sep 13;106(9):dju246. doi: 10.1093/jnci/dju246. Print 2014 Sep. J Natl Cancer Inst. 2014. PMID: 25217772 Free PMC article.
Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, From L, Busam KJ, Hao H, Orlow I, Kanetsky PA, Luo L, Reiner AS, Paine S, Frank JS, Bramson JI, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group. Thomas NE, et al. JAMA Oncol. 2015 Jun;1(3):359-68. doi: 10.1001/jamaoncol.2015.0493. JAMA Oncol. 2015. PMID: 26146664 Free PMC article.
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, Schimming T, Livingstone E, Sucker A, Grabellus F, Metz C, Süsskind D, Hillen U, Speicher MR, Woodman SE, Steuhl KP, Schadendorf D. Griewank KG, et al. Clin Cancer Res. 2013 Jun 15;19(12):3143-52. doi: 10.1158/1078-0432.CCR-13-0163. Epub 2013 Apr 30. Clin Cancer Res. 2013. PMID: 23633454
399 results